SB 204990

Cat. No. 4962 6 Citations Submit a Review Datasheet / COA / SDS

Pricing	Availability		Qty

Description: ATP citrate lyase (ACLY) inhibitor

Chemical Name: (3R,5S)-rel-5-[6-(2,4-Dichlorophenyl)hexyl]tetrahydro-3-hydroxy-2-oxo-3-furanacetic acid

Purity: ≥98% (HPLC)

Datasheet

Citations (6)

Reviews

Biological Activity Technical Data Solubility Calculators Datasheets References

Biological Activity for SB 204990

SB 204990 is an ATP citrate lyase (ACLY) inhibitor; it is a prodrug of SB 201076. SB 204990 inhibits cholesterol and fatty acid synthesis in a dose-dependent manner in HepG2 cells. Suppresses growth of cancer cells showing aerobic glycolysis in vitro and in vivo. Orally active.

Licensing Information

Sold for research purposes under agreement from GlaxoSmithKline

Compound Libraries for SB 204990

SB 204990 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for SB 204990

M. Wt	389.27
Formula	C₁₈H₂₂Cl₂O₅
Storage	Store at -20°C
Purity	≥98% (HPLC)
CAS Number	154566-12-8
PubChem ID	10340264
InChI Key	YTRNLFYTHYWDAU-KDOFPFPSSA-N
Smiles	ClC(C=C(Cl)C=C2)=C2CCCCCC[C@@H](OC1=O)C[C@]1(O)CC(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for SB 204990

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMSO	38.93	100
	ethanol	38.93	100

Preparing Stock Solutions for SB 204990

The following data is based on the product molecular weight 389.27. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.57 mL	12.84 mL	25.69 mL
5 mM	0.51 mL	2.57 mL	5.14 mL
10 mM	0.26 mL	1.28 mL	2.57 mL
50 mM	0.05 mL	0.26 mL	0.51 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

Product Datasheets for SB 204990

Certificate of Analysis / Product Datasheet

Safety Datasheet

References for SB 204990

References are publications that support the biological activity of the product.

Pearce et al (1998) The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem.J. 334 113 PMID: 9693110

Gribble et al (1998) ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R*,5S*)-ω-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzy J.Med.Chem. 41 3582 PMID: 9733484

Hatzivassiliou et al (2005) ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8 311 PMID: 16226706

If you know of a relevant reference for SB 204990, please let us know.

View Related Products by Target

View Related Products by Product Action

View all ATP Citrate Lyase Inhibitors

Keywords: SB 204990, SB 204990 supplier, SB204990, ATP-citrate, lyases, ACL, inhibitors, inhibits, prodrug, SB-201076, cholesterol, fatty, acid, metabolic, lipids, synthases, transferases, ACLY, ATP, Citrate, Lyase, 4962, Tocris Bioscience